<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03202836</url>
  </required_header>
  <id_info>
    <org_study_id>230/2017</org_study_id>
    <nct_id>NCT03202836</nct_id>
  </id_info>
  <brief_title>Vaginal Progesterone Supplementation in the Management of Preterm Labor</brief_title>
  <official_title>Vaginal Progesterone Supplementation in the Management of Preterm Labor: A Randomized, Double Blind, Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chulalongkorn University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chulalongkorn University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the addition of vaginal progesterone in the management of preterm labor.
      Half of participants will receive vaginal progesterone, tocolysis and corticosteroid, while
      the other half will receive only tocolysis and corticosteroid.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 29, 2017</start_date>
  <completion_date type="Anticipated">June 30, 2018</completion_date>
  <primary_completion_date type="Anticipated">March 29, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time from preterm labor pain to delivery</measure>
    <time_frame>9 weeks</time_frame>
    <description>time since preterm labor to delivery</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>gestational age at delivery</measure>
    <time_frame>9 weeks</time_frame>
    <description>gestational age at birth</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of pregnant women deliver before 34 weeks</measure>
    <time_frame>6 weeks</time_frame>
    <description>preterm birth &lt; 34 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of pregnant women deliver before 37 weeks</measure>
    <time_frame>9 weeks</time_frame>
    <description>preterm birth &lt; 37 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of newborn with respiratory distress syndrome</measure>
    <time_frame>9 weeks</time_frame>
    <description>Number of newborn with respiratory distress syndrome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of newborn with intraventricular hemorrhage</measure>
    <time_frame>9 weeks</time_frame>
    <description>Number of newborn with intraventricular hemorrhage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of newborn with necrotizing enterocolitis</measure>
    <time_frame>9 weeks</time_frame>
    <description>Number of newborn with necrotizing enterocolitis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of newborn with sepsis</measure>
    <time_frame>9 weeks</time_frame>
    <description>Number of newborn with sepsis</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">86</enrollment>
  <condition>Preterm Labor</condition>
  <arm_group>
    <arm_group_label>vaginal progesterone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vaginal utrogestan 400 mg, vaginal suppository, once at bed time until gestational age 37 weeks and tocolysis plus corticosteroid for 48 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>no medication</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>only tocolysis plus corticosteroid for 48 hours</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>progesterone</intervention_name>
    <description>vaginal utrogestan</description>
    <arm_group_label>vaginal progesterone</arm_group_label>
    <other_name>utrogestan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tocolytics</intervention_name>
    <description>tocolysis for 48 hours</description>
    <arm_group_label>vaginal progesterone</arm_group_label>
    <arm_group_label>no medication</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Steroids</intervention_name>
    <description>antenatal corticosteroids for 48 hours</description>
    <arm_group_label>vaginal progesterone</arm_group_label>
    <arm_group_label>no medication</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  singleton pregnant women with preterm labor, gestational age 24-34 weeks

        Exclusion Criteria:

          -  have indicated preterm birth

          -  allergy to progesterone

          -  fetal anomalies

          -  cervical dilate &gt; 5 cm.

          -  have medical disease

          -  have obstetric complication
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vorapong Phupong, MD</last_name>
    <role>Study Director</role>
    <affiliation>Chulalongkorn University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Vorapong Phupong, MD</last_name>
    <phone>26492115</phone>
    <email>vorapong.p@chula.ac.th</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rattanawadee Sirisangworn, MD</last_name>
    <phone>26492115</phone>
    <email>rattanawadee.sw14@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Faculty of Medicine, Chulalongkorn University</name>
      <address>
        <city>Bangkok</city>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vorapong Phupong, MD</last_name>
      <phone>26492115</phone>
      <email>vorapong.p@chula.ac.th</email>
    </contact>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <reference>
    <citation>O'Brien JM. Vaginal progesterone prophylaxis for preterm birth. Lancet. 2016 Sep 17;388(10050):1159-60. doi: 10.1016/S0140-6736(16)31614-2. Epub 2016 Sep 16.</citation>
    <PMID>27650091</PMID>
  </reference>
  <reference>
    <citation>Azargoon A, Ghorbani R, Aslebahar F. Vaginal progesterone on the prevention of preterm birth and neonatal complications in high risk women: A randomized placebo-controlled double-blind study. Int J Reprod Biomed (Yazd). 2016 May;14(5):309-16.</citation>
    <PMID>27326415</PMID>
  </reference>
  <reference>
    <citation>Elimian A, Smith K, Williams M, Knudtson E, Goodman JR, Escobedo MB. A randomized controlled trial of intramuscular versus vaginal progesterone for the prevention of recurrent preterm birth. Int J Gynaecol Obstet. 2016 Aug;134(2):169-72. doi: 10.1016/j.ijgo.2016.01.010. Epub 2016 Apr 18.</citation>
    <PMID>27168167</PMID>
  </reference>
  <reference>
    <citation>Conde-Agudelo A, Romero R. Vaginal progesterone to prevent preterm birth in pregnant women with a sonographic short cervix: clinical and public health implications. Am J Obstet Gynecol. 2016 Feb;214(2):235-242. doi: 10.1016/j.ajog.2015.09.102. Epub 2015 Oct 9.</citation>
    <PMID>26450404</PMID>
  </reference>
  <reference>
    <citation>Romero R. Vaginal progesterone to reduce the rate of preterm birth and neonatal morbidity: a solution at last. Womens Health (Lond). 2011 Sep;7(5):501-4. doi: 10.2217/whe.11.60.</citation>
    <PMID>21879816</PMID>
  </reference>
  <reference>
    <citation>Hassan SS, Romero R, Vidyadhari D, Fusey S, Baxter JK, Khandelwal M, Vijayaraghavan J, Trivedi Y, Soma-Pillay P, Sambarey P, Dayal A, Potapov V, O'Brien J, Astakhov V, Yuzko O, Kinzler W, Dattel B, Sehdev H, Mazheika L, Manchulenko D, Gervasi MT, Sullivan L, Conde-Agudelo A, Phillips JA, Creasy GW; PREGNANT Trial. Vaginal progesterone reduces the rate of preterm birth in women with a sonographic short cervix: a multicenter, randomized, double-blind, placebo-controlled trial. Ultrasound Obstet Gynecol. 2011 Jul;38(1):18-31. doi: 10.1002/uog.9017. Epub 2011 Jun 15.</citation>
    <PMID>21472815</PMID>
  </reference>
  <reference>
    <citation>da Fonseca EB, Bittar RE, Carvalho MH, Zugaib M. Prophylactic administration of progesterone by vaginal suppository to reduce the incidence of spontaneous preterm birth in women at increased risk: a randomized placebo-controlled double-blind study. Am J Obstet Gynecol. 2003 Feb;188(2):419-24.</citation>
    <PMID>12592250</PMID>
  </reference>
  <results_reference>
    <citation>Palacio M, Cobo T, Antolín E, Ramirez M, Cabrera F, Mozo de Rosales F, Bartha JL, Juan M, Martí A, Oros D, Rodríguez À, Scazzocchio E, Olivares JM, Varea S, Ríos J, Gratacós E; PROMISE Collaborative Group. Vaginal progesterone as maintenance treatment after an episode of preterm labour (PROMISE) study: a multicentre, double-blind, randomised, placebo-controlled trial. BJOG. 2016 Nov;123(12):1990-1999. doi: 10.1111/1471-0528.13956. Epub 2016 Mar 30.</citation>
    <PMID>27028759</PMID>
  </results_reference>
  <results_reference>
    <citation>Martinez de Tejada B, Karolinski A, Ocampo MC, Laterra C, Hösli I, Fernández D, Surbek D, Huespe M, Drack G, Bunader A, Rouillier S, López de Degani G, Seidenstein E, Prentl E, Antón J, Krähenmann F, Nowacki D, Poncelas M, Nassif JC, Papera R, Tuma C, Espoile R, Tiberio O, Breccia G, Messina A, Peker B, Schinner E, Mol BW, Kanterewicz L, Wainer V, Boulvain M, Othenin-Girard V, Bertolino MV, Irion O; 4P trial group. Prevention of preterm delivery with vaginal progesterone in women with preterm labour (4P): randomised double-blind placebo-controlled trial. BJOG. 2015 Jan;122(1):80-91. doi: 10.1111/1471-0528.13061. Epub 2014 Sep 11.</citation>
    <PMID>25209926</PMID>
  </results_reference>
  <results_reference>
    <citation>Borna S, Sahabi N. Progesterone for maintenance tocolytic therapy after threatened preterm labour: a randomised controlled trial. Aust N Z J Obstet Gynaecol. 2008 Feb;48(1):58-63. doi: 10.1111/j.1479-828X.2007.00803.x.</citation>
    <PMID>18275573</PMID>
  </results_reference>
  <results_reference>
    <citation>Arikan I, Barut A, Harma M, Harma IM. Effect of progesterone as a tocolytic and in maintenance therapy during preterm labor. Gynecol Obstet Invest. 2011;72(4):269-73. doi: 10.1159/000328719. Epub 2011 Nov 12.</citation>
    <PMID>22086108</PMID>
  </results_reference>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 24, 2017</study_first_submitted>
  <study_first_submitted_qc>June 27, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 29, 2017</study_first_posted>
  <last_update_submitted>August 2, 2017</last_update_submitted>
  <last_update_submitted_qc>August 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 3, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chulalongkorn University</investigator_affiliation>
    <investigator_full_name>Vorapong Phupong</investigator_full_name>
    <investigator_title>Head of Placental Related Diseases Research Unit</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Premature Birth</mesh_term>
    <mesh_term>Obstetric Labor, Premature</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Progesterone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

